The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis

Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis

August 20, 2018 • By Lorraine L. Janeczko

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—In patients with active non-radiographic axial spondyloarthritis (nr-axSpA) who achieved remission while taking adalimumab, researchers saw fewer flares among those who continued taking the drug than among those who stopped taking it.

You Might Also Like
  • Subcutaneous Golimumab in Active Non-Radiographic Axial Spondyloarthritis
  • FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA
  • EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis

“The results showed that continued therapy with adalimumab was associated with a higher rate of maintenance of remission compared with treatment withdrawal,” the authors write in The Lancet, online June 28.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The ABILITY-3 trial, led by Dr. Robert Landewe of Amsterdam Rheumatology & Clinical Immunology Center, enrolled adults in 20 countries with nr-axSpA who had objective evidence of active inflammation, active disease, and inadequate response to at least two non-steroidal anti-inflammatory drugs.

During the 28-week lead-in period, all 673 participants received 40 mg subcutaneous adalimumab every other week for 28 weeks. The 305 patients who achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS) less than 1.3 at Weeks 16, 20, 24 and 28, were randomly assigned to 40 weeks of treatment with adalimumab or placebo.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients who experienced a flare (ASDAS 2.1 or higher at two consecutive visits) during the 40-week period received 12 weeks of rescue therapy with 40 mg open-label adalimumab every other week; original treatment allocation remained blinded.

More patients continuing adalimumab were free of flares (70% vs. 47%; P<0.0001) through Week 68.

Of the 673 patients who received adalimumab at any time, 516 (77%) reported an adverse event, and 28 (4%) reported a serious adverse event. The most common adverse events in both groups were nasopharyngitis, upper respiratory tract infection, and axSpA worsening.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Jurgen Braun of the Department of Rheumatology of Ruhr University Bochum in Germany tells Reuters Health by email, “I was a bit surprised about the high number of patients who were still in drug-free remission at the end of the observation period.”

“We need to know how many patients continue to be in remission after discontinuation and whether it is possible to predict who will not benefit from readministration,” adds Dr. Braun, who wrote an invited commentary about the study.2

“I think these results will make it easier to try the biologic and see whether it can be discontinued,” he says. “However, we will need to know more about the best time to discontinue and the clinical status of the patients at time of discontinuation, including magnetic resonance imagery and C-reactive protein values. We also need data on dose reduction strategies and studies in ankylosing spondylitis.”

“The main task for rheumatologists will remain to identify and treat axSpA patients in need for biologic therapy as early as possible,” Dr. Braun advises. “Some of them may have to be treated for a lifetime, for others it may be possible to reduce the dose, and for some it may even be possible to follow an on-demand strategy with intermediate discontinuation of therapy when ongoing remission is achieved.”

Pages: 1 2 | Single Page

Filed Under: Conditions, Spondyloarthritis Tagged With: adalimumab, axial spondyloarthritis (SpA), non-radiographic axial spondyloarthritis, Remission

You Might Also Like:
  • Subcutaneous Golimumab in Active Non-Radiographic Axial Spondyloarthritis
  • FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA
  • EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)